On this page
PYGM
glycogen phosphorylase, muscle associated
The PYGM gene encodes myophosphorylase, an enzyme essential for glycogen breakdown in muscle cells, with pathogenic variants causing Glycogen Storage Disease Type V (GSD V). PYGM provides instructions for an enzyme called myophosphorylase, which is vital for energy production in muscle cells.
PYGM is located on the long (q) arm of chromosome 11, at band 11q13.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 11 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The PYGM gene, or glycogen phosphorylase, muscle associated, is responsible for producing the myophosphorylase enzyme. This enzyme plays a critical role in carbohydrate metabolism, specifically within muscle tissues. Myophosphorylase facilitates the breakdown of glycogen, a stored form of glucose, into a readily usable sugar for muscle energy.
Disruptions to the PYGM gene's function can lead to an inability of muscle cells to adequately break down glycogen, resulting in an accumulation of glycogen and impaired energy supply. This genetic alteration forms the basis of Glycogen Storage Disease Type V.
What the gene does
The PYGM gene instructs the synthesis of myophosphorylase, one of three related glycogen phosphorylase enzymes. Myophosphorylase is specifically expressed in muscle cells, where it functions to break down glycogen, a complex carbohydrate, into glucose-1-phosphate. This process is the initial step in converting stored glycogen into glucose, which serves as the primary energy source for cellular functions.
Glycogen breakdown is crucial for muscles, especially during physical activity, to maintain a continuous supply of energy. Myophosphorylase ensures that muscle cells can rapidly access their stored energy reserves by converting glycogen into a form that can enter metabolic pathways to produce ATP, the cell's main energy currency. A deficiency in this enzyme significantly impacts muscle energy metabolism.
Video: Genetics 101
Chromosome location
The PYGM gene is situated on chromosome 11, specifically at the band 11q13.1. This location indicates its position on the long (q) arm of chromosome 11. The gene provides the genetic blueprint for a protein composed of 842 amino acids.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein.
Key variants
Variations within the PYGM gene can affect the production or function of the myophosphorylase enzyme. These genetic changes can range from single nucleotide substitutions to larger deletions or insertions, and their impact varies depending on the specific alteration. Pathogenic variants can lead to a reduction in enzyme activity or complete absence of the protein.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.125del | p.Lys42fs | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.134del | p.Asn45fs | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.1363G>C | p.Gly455Arg | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.2040_2041insCC | p.Lys681fs | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.2075_2076delinsAAA | p.Thr692fs | Pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.2146dup | p.Val716fs | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.485_486del | p.Arg161_Tyr162insTer | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.505C>T | p.Gln169Ter | Pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.580del | p.Arg194fs | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
c.658C>T | p.Gln220Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Glycogen storage disease, type V |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the PYGM gene are primarily associated with Glycogen Storage Disease Type V (GSD V), also known as McArdle disease. This condition is inherited in an autosomal recessive pattern. Individuals with GSD V typically experience muscle pain, stiffness, and fatigue, particularly during exercise, due to the muscles' inability to properly break down glycogen for energy.
Inheritance pattern
Conditions caused by pathogenic PYGM variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
The PYGM gene is included on several NHS Genomic Medicine Service clinical panels, indicating its relevance in diagnosing specific inherited conditions within the UK. It is featured on panels for Acute rhabdomyolysis, Foetal anomalies, Glycogen storage disease, Glycogen storage disease V, Hyperammonaemia, Likely inborn error of metabolism, Limb girdle muscular dystrophies, myofibrillar myopathies and distal myopathies, Retinal disorders, Rhabdomyolysis and metabolic muscle disorders, Skeletal Muscle Channelopathies, Skeletal muscle channelopathy, and Undiagnosed metabolic disorders.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the role of the PYGM gene?
The PYGM gene provides instructions for making myophosphorylase, an enzyme found in muscle cells. This enzyme is crucial for breaking down glycogen into a usable sugar, which powers muscle activity, especially during exercise.
What health condition is linked to the PYGM gene?
Variants in the PYGM gene are associated with Glycogen Storage Disease Type V (GSD V), also known as McArdle disease. This condition affects the muscles' ability to use stored glycogen for energy, leading to symptoms like muscle pain and fatigue during physical activity.
How is Glycogen Storage Disease Type V inherited?
Glycogen Storage Disease Type V (GSD V) is inherited in an autosomal recessive pattern. This means an individual must inherit two altered copies of the PYGM gene, one from each parent, to develop the condition. Individuals with only one altered copy are typically carriers and do not show symptoms.
References
- Nogales-Gadea G, Rubio JC, Fernandez-Cadenas I. Expression of the muscle glycogen phosphorylase gene in patients with McArdle disease: the role of nonsense-mediated mRNA decay. Human mutation. 2008. PMID: 17994553
- Nogales-Gadea G, Arenas J, Andreu AL. Molecular genetics of McArdle's disease. Current neurology and neuroscience reports. 2007. PMID: 17217859
- Aquaron R, Bergé-Lefranc JL, Pellissier JF. Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: identification of 10 new mutations. Absence of genotype-phenotype correlation. Neuromuscular disorders : NMD. 2007. PMID: 17324573
- Deschauer M, Morgenroth A, Joshi PR. Analysis of spectrum and frequencies of mutations in McArdle disease. Identification of 13 novel mutations. Journal of neurology. 2007. PMID: 17404776
- Bruno C, Cassandrini D, Martinuzzi A. McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Human mutation. 2006. PMID: 16786513